{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:50:42Z","timestamp":1792673442412,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["232300421119"],"award-info":[{"award-number":["232300421119"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019331","name":"Henan Medical Science and Technique Foundation","doi-asserted-by":"publisher","award":["SBGJ202302029"],"award-info":[{"award-number":["SBGJ202302029"]}],"id":[{"id":"10.13039\/501100019331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019331","name":"Henan Medical Science and Technique Foundation","doi-asserted-by":"publisher","award":["SBGJ202301004"],"award-info":[{"award-number":["SBGJ202301004"]}],"id":[{"id":"10.13039\/501100019331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573686"],"award-info":[{"award-number":["82573686"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189572","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T20:48:52Z","timestamp":1773002932000},"page":"189572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current research status and challenges of neoadjuvant immunotherapy for Esophageal squamous cell carcinoma"],"prefix":"10.1016","volume":"1881","author":[{"given":"Wanying","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shegan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2026.189572_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189572_bb0010","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1007\/s11427-022-2240-6","article-title":"Overview and countermeasures of cancer burden in China","volume":"66","author":"Wang","year":"2023","journal-title":"Sci. China Life Sci."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189572_bb0015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/JS9.0000000000000347","article-title":"Prediction of conditional survival in esophageal cancer in a population-based cohort study","volume":"109","author":"Xie","year":"2023","journal-title":"Int. J. Surgery (London, England)"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189572_bb0020","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189572_bb0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, Version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189572_bb0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189572_bb0040","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0045","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189572_bb0050","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189572_bb0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0060","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01845-4","article-title":"Beyond the anti-PD-1\/PD-L1 era: promising role of the BTLA\/HVEM axis as a future target for cancer immunotherapy","volume":"22","author":"Sordo-Bahamonde","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0070","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189572_bb0075","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41422-020-0333-6","article-title":"Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma","volume":"30","author":"Cui","year":"2020","journal-title":"Cell Res."},{"issue":"18","key":"10.1016\/j.bbcan.2026.189572_bb0080","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1097\/CM9.0000000000002371","article-title":"Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy","volume":"135","author":"Yan","year":"2022","journal-title":"Chin. Med. J."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189572_bb0085","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189572_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007847","article-title":"High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy","volume":"11","author":"Han","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"6695","key":"10.1016\/j.bbcan.2026.189572_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/science.adj4857","article-title":"A blueprint for tumor-infiltrating B cells across human cancers","volume":"384","author":"Ma","year":"2024","journal-title":"Science (New York, NY)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/cas.16006","article-title":"Inhibition of transforming growth factor-\u03b2 signals suppresses tumor formation by regulation of tumor microenvironment networks","volume":"115","author":"Tokizaki","year":"2024","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189572_bb0105","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.bbcan.2026.189572_bb0110","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.bbcan.2026.189572_bb0115","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189572_bb0120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg."},{"key":"10.1016\/j.bbcan.2026.189572_bb0125","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189572_bb0130","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ccell.2024.09.008","article-title":"A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: the Keystone-001 trial","volume":"42","author":"Shang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189572_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189572_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189572_bb0150","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189572_bb0155","article-title":"Conversion surgery following immunochemotherapy in initially unresectable locally advanced esophageal squamous cell carcinoma-a real-world multicenter study (RICE-Retro)","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189572_bb0160","volume":"12","author":"Shang","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189572_bb0165","first-page":"561","article-title":"Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations","volume":"6","author":"Raufi","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189572_bb0170","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189572_bb0175","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0180","volume":"17","author":"Tang","year":"2017","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189572_bb0185","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","article-title":"Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT)","volume":"27","author":"van den Ende","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189572_bb0190","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03769-4","article-title":"First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial","volume":"73","author":"Zhao","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189572_bb0195","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189572_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1312380","article-title":"To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment","volume":"15","author":"Yehan","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189572_bb0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00262-025-04076-2","article-title":"LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy","volume":"74","author":"Zhang","year":"2025","journal-title":"Cancer Immunol. Immunotherapy: CII"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189572_bb0210","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-025-01666-6","article-title":"Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib\/II trial","volume":"18","author":"Chen","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189572_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7235","article-title":"Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial","volume":"13","author":"Kato","year":"2024","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189572_bb0225","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doac031","article-title":"Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China","volume":"35","author":"Yang","year":"2022","journal-title":"Dis. Esophagus"},{"issue":"10302","key":"10.1016\/j.bbcan.2026.189572_bb0230","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10388-025-01165-0","article-title":"Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29)","volume":"23","author":"Hong","year":"2026","journal-title":"Esophagus"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189572_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189572_bb0245","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ccell.2023.03.016","article-title":"An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.bbcan.2026.189572_bb0250","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0255","article-title":"Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy","volume":"5","author":"Cheng","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189572_bb0260","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7103","article-title":"Gastroesophageal adenocarcinomas with defective mismatch repair: current knowledge and clinical management","volume":"22","author":"Strickland","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0265","article-title":"Clinicopathological characteristics and the relationship of PD-L1 status, tumor mutation burden, and microsatellite instability in patients with esophageal carcinoma","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0270","article-title":"The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189572_bb0275","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1245\/s10434-024-16288-4","article-title":"The relationship between gut microbiome Bifidobacterium and anti-tumor immune responses in esophageal squamous cell carcinoma","volume":"32","author":"Wang","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189572_bb0280","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/JS9.0000000000002341","article-title":"TP53-centric ctDNA complements PET\/CT for non-invasive assessment of pathological complete response and survival after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a prospective cohort study","volume":"111","author":"Yang","year":"2025","journal-title":"Int. J. Surg."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189572_bb0285","article-title":"ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189572_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217866","article-title":"Identification of an individualized immune-related miRNA pair signature for survival prediction of neoadjuvant chemoradiotherapy in esophageal squamous cell cancer","volume":"629","author":"Wu","year":"2025","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189572_bb0295","article-title":"Targeted therapies and immunotherapies in the treatment of esophageal cancers","volume":"7","author":"Barsouk","year":"2019","journal-title":"Med. Sci."},{"issue":"7498","key":"10.1016\/j.bbcan.2026.189572_bb0300","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature13176","article-title":"Identification of genomic alterations in oesophageal squamous cell cancer","volume":"509","author":"Song","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0305","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-07787-7","article-title":"ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0310","article-title":"Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-01864-0","article-title":"IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma","volume":"10","author":"Wu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"29","key":"10.1016\/j.bbcan.2026.189572_bb0320","article-title":"TAOK3 facilitates esophageal squamous cell carcinoma progression and cisplatin resistance through augmenting autophagy mediated by IRGM","volume":"10","author":"Sun","year":"2023","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemb., Ger.)"},{"issue":"22","key":"10.1016\/j.bbcan.2026.189572_bb0325","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/1759-7714.14997","article-title":"Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.bbcan.2026.189572_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112364","article-title":"Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma","volume":"137","author":"Jin","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189572_bb0335","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.bbcan.2026.189572_bb0340","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189572_bb0345","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"issue":"35","key":"10.1016\/j.bbcan.2026.189572_bb0350","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0355","article-title":"Clinical efficacy of different neoadjuvant therapies for resectable esophageal squamous cell carcinoma","volume":"23","author":"Wang","year":"2025","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189572_bb0360","article-title":"Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189572_bb0365","article-title":"The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: a real-world study","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:42:35Z","timestamp":1782031355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X26000442"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189572","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current research status and challenges of neoadjuvant immunotherapy for Esophageal squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189572"}}